Xilio Therapeutics (XLO) Other Accumulated Expenses (2020 - 2026)
Xilio Therapeutics (XLO) posted Other Accumulated Expenses of $198000.0 for Q1 2026, up 138.55% sequentially from $83000.0 in Q4 2025, and up 17.86% YoY from $168000.0 in Q1 2025.
Xilio Therapeutics (XLO) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Other Accumulated Expenses for 7 years, with the latest figure at $198000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 17.86% year-over-year to $198000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198000.0 (up 17.86% YoY) and the FY2025 annual result came in at $83000.0, down 36.64% from the prior year.
- Other Accumulated Expenses rose to $198000.0 in Q1 2026 per XLO's latest filing, from $83000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $305000.0 in Q2 2022 and troughed at $7000.0 in Q2 2024.
- A 5-year average of $132235.3 and a median of $109000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 91.46% in 2024, then surged 2700.0% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $82000.0 in 2022, then sank by 41.46% to $48000.0 in 2023, then jumped by 172.92% to $131000.0 in 2024, then plunged by 36.64% to $83000.0 in 2025, then soared by 138.55% to $198000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $198000.0, $83000.0, and $88000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94,000.00 |
| Mar 31, 2026 | 198,000.00 |
| Dec 31, 2025 | 83,000.00 |
| Sep 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 196,000.00 |
| Mar 31, 2025 | 168,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 109,000.00 |
| Dec 31, 2023 | 48,000.00 |
| Sep 30, 2023 | 68,000.00 |
| Jun 30, 2023 | 82,000.00 |
| Mar 31, 2023 | 269,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Sep 30, 2022 | 82,000.00 |
| Jun 30, 2022 | 305,000.00 |
| Mar 31, 2022 | 194,000.00 |
| Dec 31, 2021 | 321,000.00 |
| Sep 30, 2021 | 82,000.00 |